IL-1beta Inhibitors & Biosimilars
2 drugsAbout IL-1beta
Interleukin-1beta (IL-1beta) is a potent pro-inflammatory cytokine that plays a critical role in the body's immune response. As a signaling protein, it mediates inflammation and has become an important drug target.
IL-1beta inhibitors have shown clinical success, underscoring its therapeutic significance in immunology. Currently, there is no genetic evidence data available linking IL-1beta to specific diseases in our dataset.
Two approved drugs target IL-1beta: KINERET (anakinra) and ARCALYST (rilonacept). These drugs are biologics (other) and fusion proteins, developed by BIOVITRUM AB and KINIKSA PHARMACEUTICALS, respectively.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Diffuse Large B-Cell Lymphoma with only 2 trials.
- Emerging modalities (Fusion protein) signal innovation opportunity.
- phase4 represents biological uncertainty with 50% completion.
Top IL-1beta Drugs
BIOVITRUM AB and KINIKSA PHARMACEUTICALS are the only two companies with approved IL-1beta drugs.
Low market concentration suggests moderate entry barriers for new companies developing IL-1beta inhibitors.
IL-1beta Drug Modality Landscape
Modalities
Routes of Administration
IL-1beta requires biologic approaches (biologic (other)), likely due to its structure or location.
Small molecule IL-1beta inhibitors represent a whitespace opportunity to expand therapeutic options.
📈 Modality Evolution
other biologics pioneered IL-1beta targeting (2001), with fusion proteins entering more recently (2008).
IL-1beta Clinical Trials 146 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 37 | 22 | 9 | 6 | 71% |
| Phase 2 | 77 | 49 | 13 | 14 | 79% |
| Phase 3 | 25 | 13 | 4 | 8 | 76% |
| Phase 4 | 7 | 2 | 2 | 3 | 50% |
Top Sponsors
By Modality
IL-1beta Drug Approval Timeline (2001 - 2008)
The first IL-1beta drug was approved in 2001 (KINERET), and the most recent in 2008 (ARCALYST).
The approval timeline suggests a potential saturation, requiring novel approaches for future drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 107 clinical trials targeting IL-1beta.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities